RELX PLC (RDEB)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 36.26 |
|---|---|
| 52-week range | 23.20 – 40.42 |
| Return, 1 month / 3 months | +26.3% / +26.8% |
| Return, 1 year / 3 years | −7.9% / +16.3% |
| Trend | Uptrend |
| RSI (14) | 85 |
| Volatility (1 year) | 36.2% |
| Worst drawdown (1 year) | -41.8% |
| Average daily value traded | 0.08M EUR |
| Dividend yield | 2.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
RELX PLC is an information and analytics company based in London. It serves researchers, lawyers, insurers and other professional customers through businesses that publish scientific journals and reference works, provide legal and business information, supply risk and insurance analytics, and organise trade exhibitions and conferences. Its products include online databases, research platforms, decision tools and industry events used by organisations in many countries.
RELX PLC trades under the code RDEB on the XETRA Stock Exchange in Germany, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
RELX PLC (RDEB) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 36.26 on 22 October 2026.
Its price-based Market X-Ray is 57 out of 100 (a fair price profile), ranking 295 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 7.9% and over the last three months it rose 26.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 78 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 23.6% | ||
| From 52-week high | -10.3% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 26.8% | ||
| 6-month return | 17.4% | ||
| 12-month return, skipping the last month | -27.0% | ||
| Stability (higher is calmer) | 40 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.8% | ||
| Liquidity | 42 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.08M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.8% |
|---|---|
| 1 month | +26.3% |
| 3 months | +26.8% |
| 6 months | +17.4% |
| 1 year | −7.9% |
| 3 years | +16.3% |
| 5 years | +50.9% |
Signals
| 50-day / 200-day average | 30.87 / 29.35 |
|---|---|
| Golden / death cross (60 days) | Golden, 33 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.74 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2026 | GBP 0.2478 |
| 7 May 2026 | GBP 0.5690 |
| 7 Aug 2025 | GBP 0.2312 |
| 8 May 2025 | GBP 0.5311 |
| 1 Aug 2024 | GBP 0.2157 |
| 2 May 2024 | GBP 0.4955 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.